CN106967076A - One kind has 6H dibenzopyrans structural compounds and preparation method thereof - Google Patents
One kind has 6H dibenzopyrans structural compounds and preparation method thereof Download PDFInfo
- Publication number
- CN106967076A CN106967076A CN201710200791.6A CN201710200791A CN106967076A CN 106967076 A CN106967076 A CN 106967076A CN 201710200791 A CN201710200791 A CN 201710200791A CN 106967076 A CN106967076 A CN 106967076A
- Authority
- CN
- China
- Prior art keywords
- reaction
- add
- dibenzopyran
- isopropoxy
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 8
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- 230000009471 action Effects 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 143
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 63
- -1 6H-dibenzopyran structure compound Chemical class 0.000 claims description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- 239000012074 organic phase Substances 0.000 claims description 45
- 239000002904 solvent Substances 0.000 claims description 45
- 239000002994 raw material Substances 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 32
- 239000003054 catalyst Substances 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 229960000583 acetic acid Drugs 0.000 claims description 15
- 239000012362 glacial acetic acid Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 238000010898 silica gel chromatography Methods 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 239000007810 chemical reaction solvent Substances 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 11
- HZLKLSRFTPNXMY-UHFFFAOYSA-N 1-methyl-3-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=CC(C)=C1 HZLKLSRFTPNXMY-UHFFFAOYSA-N 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims description 10
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 10
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 claims description 10
- BEUDCHGZCTUAOG-UHFFFAOYSA-N 6h-benzo[c]chromene Chemical group C1=CC=C2COC3=CC=CC=C3C2=C1 BEUDCHGZCTUAOG-UHFFFAOYSA-N 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 9
- 238000010791 quenching Methods 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 7
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007868 Raney catalyst Substances 0.000 claims description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 5
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 5
- XYMZAFDNPJLOTP-UHFFFAOYSA-N methyl 2-bromo-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C=C1Br XYMZAFDNPJLOTP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 235000010288 sodium nitrite Nutrition 0.000 claims description 5
- 239000005909 Kieselgur Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000006479 redox reaction Methods 0.000 claims description 4
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- TZIHFWKZFHZASV-UHFFFAOYSA-N anhydrous methyl formate Natural products COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 239000010937 tungsten Substances 0.000 claims description 3
- MOJMMFDDUPTSLH-UHFFFAOYSA-N (2-aminophenyl)boron Chemical compound [B]C1=CC=CC=C1N MOJMMFDDUPTSLH-UHFFFAOYSA-N 0.000 claims description 2
- 229920003026 Acene Polymers 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 102000008175 FSH Receptors Human genes 0.000 abstract description 9
- 108010060374 FSH Receptors Proteins 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 239000005557 antagonist Substances 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000027272 reproductive process Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- DMGNFLJBACZMRM-UHFFFAOYSA-N O[P] Chemical compound O[P] DMGNFLJBACZMRM-UHFFFAOYSA-N 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- STCDDNDGEFVYKE-UHFFFAOYSA-N diphenylphosphane;propane Chemical compound CCC.C=1C=CC=CC=1PC1=CC=CC=C1.C=1C=CC=CC=1PC1=CC=CC=C1 STCDDNDGEFVYKE-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- DYFCVTZDVBEFPD-UHFFFAOYSA-N methyl 2h-pyran-2-carboxylate Chemical compound COC(=O)C1OC=CC=C1 DYFCVTZDVBEFPD-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域technical field
本发明属于医药中间体的合成技术领域,具体涉及一种具有6H-二苯并吡喃结构化合物及其制备方法。The invention belongs to the technical field of synthesis of pharmaceutical intermediates, and specifically relates to a compound with a 6H-dibenzopyran structure and a preparation method thereof.
背景技术Background technique
促性腺激素在人体中表现出重要的生理机能,比如新陈代谢、体温调节和生殖过程。它是由下丘脑合成和分泌的,通过诱导垂体中促卵泡激素(FSH)/黄体生成激素(LH)的分泌,并进一步诱导卵巢中各级卵泡的生长发育及排卵。FSH是哺乳动物生殖过程中的核心激素,在胎儿性分化、胎儿期卵子峰发生和卵泡闭锁、性成熟期卵泡的发生发育和成熟、颗粒细胞芳香化酶活化和雄激素向雌激素的转化、生殖周期的调节中起到不可替代的关键作用。FSH对靶器官的作用主要由FSH受体(FSHR)所介导。研究表明,FSHR不仅只表达于性腺,也在骨骼、前列腺、卵巢表面上皮等其它组织的表达。FSH在体内水平过高,会导致骨质流失,一些激素依赖性疾病,如卵巢癌、前列腺癌、子宫内膜异位、卵巢过度刺激综合征等,都受FSH影响很大;通过抑制FSH的分泌,可以进而抑制性腺分泌性激素,导致血中疾病依赖性激素水平降低,抑制癌细胞的生长或预防、缓解、治疗其他病症;例如,西曲瑞克就是按照该机理对卵巢癌发挥抗增殖效应。我们根据目前已有的FSH受体抑制剂药物分子,通过计算机药物辅助设计,对其中一个比较好的药物结构进行优化,通过新的合成方法得到了一种具有6H-二苯并吡喃结构化合物,并对其进行了相关活性测试。Gonadotropins exhibit important physiological functions in humans, such as metabolism, thermoregulation, and reproductive processes. It is synthesized and secreted by the hypothalamus, by inducing the secretion of follicle-stimulating hormone (FSH)/luteinizing hormone (LH) in the pituitary gland, and further inducing the growth and development of follicles at all levels in the ovary and ovulation. FSH is the core hormone in the reproductive process of mammals. It plays a role in fetal sexual differentiation, fetal oocyte peak generation and follicular atresia, development and maturation of sexually mature follicles, activation of granulosa cell aromatase and conversion of androgen to estrogen, reproductive It plays an irreplaceable key role in the regulation of the cycle. The effect of FSH on target organs is mainly mediated by the FSH receptor (FSHR). Studies have shown that FSHR is not only expressed in gonads, but also expressed in other tissues such as bone, prostate, and ovarian surface epithelium. Excessive levels of FSH in the body can lead to bone loss. Some hormone-dependent diseases, such as ovarian cancer, prostate cancer, endometriosis, ovarian hyperstimulation syndrome, etc., are greatly affected by FSH; Secretion, which can further inhibit the secretion of sex hormones by the gonads, resulting in a decrease in the level of disease-dependent hormones in the blood, inhibiting the growth of cancer cells or preventing, alleviating, and treating other diseases; for example, cetrorelix exerts anti-proliferative effects on ovarian cancer according to this mechanism. Based on the existing FSH receptor inhibitor drug molecules, we optimized the structure of one of the better drugs through computer drug-aided design, and obtained a compound with a 6H-dibenzopyran structure through a new synthesis method , and tested its activity.
发明内容Contents of the invention
本发明解决的技术问题是提供了一种合成方法简单、分子结构新颖且对FSH受体作用效果较好的一种具有6H-二苯并吡喃结构化合物及其制备方法。The technical problem solved by the invention is to provide a compound with a 6H-dibenzopyran structure and a preparation method thereof, which has a simple synthesis method, a novel molecular structure and a good effect on FSH receptors.
本发明为解决上述技术问题采用如下技术方案,一种具有6H-二苯并吡喃结构化合物,其特征在于该化合物的结构式为:The present invention adopts following technical scheme in order to solve the above-mentioned technical problem, a kind of compound with 6H-dibenzopyran structure is characterized in that the structural formula of this compound is:
。 .
一种具有6H-二苯并吡喃结构化合物的制备方法,其特征在于具体步骤为:A method for preparing a compound with a 6H-dibenzopyran structure, characterized in that the specific steps are:
A、2-溴-4-硝基苯甲酸甲酯与2-氨基苯硼酸在催化剂四(三苯基膦)钯的作用下发生取代反应得到2’-氨基-5-硝基联苯-2-甲酸甲酯;A, 2-bromo-4-nitrobenzoic acid methyl ester and 2-aminophenylboronic acid have a substitution reaction under the effect of catalyst tetrakis (triphenylphosphine) palladium to obtain 2'-amino-5-nitrobiphenyl-2 - methyl formate;
B、2’-氨基-5-硝基联苯-2-甲酸甲酯在催化剂还原铁粉的作用下发生硝基还原反应得到2’-氨基-5-氨基联苯-2-甲酸甲酯;B, 2'-amino-5-nitrobiphenyl-2-methyl carboxylate undergoes a nitro reduction reaction under the action of catalyst reducing iron powder to obtain 2'-amino-5-aminobiphenyl-2-methyl carboxylate;
C、2’-氨基-5-氨基联苯-2-甲酸甲酯在催化剂亚硝酸钠的作用下经过氨基还原氧化反应得到2’-氨基-5-羟基联苯-2-甲酸甲酯;C, 2'-amino-5-aminobiphenyl-2-formic acid methyl ester obtains 2'-amino-5-hydroxybiphenyl-2-formic acid methyl ester through amino reduction oxidation reaction under the effect of catalyst sodium nitrite;
D、3-羟基甲苯和2-溴丙烷发生取代反应得到3-异丙氧基甲苯;D, 3-hydroxytoluene and 2-bromopropane undergo a substitution reaction to obtain 3-isopropoxytoluene;
E、3-异丙氧基甲苯在定位催化剂铁粉的作用下与溴素发生取代反应得到3-异丙氧基-6-溴苄溴;E, 3-isopropoxytoluene is replaced with bromine under the effect of positioning catalyst iron powder to obtain 3-isopropoxy-6-bromobenzyl bromide;
F、2’-氨基-5-羟基联苯-2-甲酸甲酯与3-异丙氧基-6-溴苄溴在羟基氢活化催化剂钯/羟基磷灰石的作用下发生取代反应得到5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯;F, 2'-amino-5-hydroxybiphenyl-2-formic acid methyl ester and 3-isopropoxy-6-bromobenzyl bromide undergo a substitution reaction under the effect of hydroxyl hydrogen activation catalyst palladium/hydroxyapatite to obtain 5 -(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl-2-carboxylic acid methyl ester;
G、5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯在苯环氢活化催化剂钯/羟基磷灰石的作用下发生分子内成环反应得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯;G, 5-(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl-2-carboxylic acid methyl ester undergoes intramolecular synthesis under the action of benzene ring hydrogen activation catalyst palladium/hydroxyapatite Ring reaction to obtain 3-(2-aminophenyl)-8-isopropoxy-6H-dibenzopyran-2-carboxylic acid methyl ester;
H、3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯在碱性溶液中发生水解后再进行酸化得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸;H, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-carboxylic acid methyl ester is hydrolyzed in alkaline solution and then acidified to obtain 3-(2-aminobenzene )-8-isopropoxy-6H-dibenzopyran-2-carboxylic acid;
I、3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸在氢化铝锂的作用下经羧基氧化还原反应得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇;1, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-formic acid obtains 3-(2-aminobenzene) through carboxyl redox reaction under the effect of lithium aluminum hydride -8-isopropoxy-6H-dibenzopyran-2-methanol;
J、3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇与对甲基磺酰氯进行羟基活化保护反应得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯;J, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methanol and p-methylsulfonyl chloride carry out hydroxyl activation protection reaction to obtain 3-(2-aminobenzene)- 8-isopropoxy-6H-dibenzopyran-2-methyl-p-methylsulfonate;
K、3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯发生取代反应进行分子内成环得到8-异丙氧基-6H-二苯并吡喃并苯基并哌啶并苯;K, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methyl p-methylsulfonate undergoes a substitution reaction for intramolecular ring formation to obtain 8-isopropoxy Base-6H-dibenzopyranophenylpiperidobenzene;
L、8-异丙氧基-6H-苯并吡喃并苯基并哌啶并苯在溴化锂的作用下脱去异丙烷基得到8-羟基-6H-二苯并吡喃并苯基并哌啶并苯;L, 8-isopropoxy-6H-benzopyranophenylpiperidobenzene removes the isopropyl group under the action of lithium bromide to obtain 8-hydroxyl-6H-dibenzopyranophenylpiperido pyrocene;
M、8-羟基-6H-二苯并吡喃并苯基并哌啶并苯与三氟甲磺酸酐反应得到8-三氟甲磺酸酯基-6H-二苯并吡喃并苯基并哌啶并苯;M, 8-hydroxyl-6H-dibenzopyranophenylpiperidinocene reacts with trifluoromethanesulfonic anhydride to obtain 8-trifluoromethanesulfonate group-6H-dibenzopyranophenyl Piperidoacene;
N、8-三氟甲磺酸酯基-6H-二苯并吡喃并苯基并哌啶并苯在催化剂1,3-双(二苯基膦)丙烷和雷尼镍的作用下与苯胺反应得到N-8-苯胺基-6H-二苯并吡喃并六氢吡啶并苯。N, 8-trifluoromethanesulfonate-6H-dibenzopyranophenylpiperidocene reacted with aniline under the catalyst of 1,3-bis(diphenylphosphino)propane and Raney nickel The reaction yields N-8-anilino-6H-dibenzopyrano-hexahydropyridocene.
进一步优选,步骤A的具体过程为:在反应容器中将2-溴-4-硝基苯甲酸甲酯、2-氨基苯硼和碳酸钾加入体积比为10:1的DME与水的混合溶液中,氮气保护下室温搅拌30min,再加入催化剂四(三苯基膦)钯,在氮气保护下搅拌均匀,升温至100℃反应直至TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入二氯甲烷中,再用纯净水洗涤两次,有机相经无水硫酸钠干燥后蒸除溶剂,再经硅胶柱层析分离提纯得到2’-氨基-5-硝基联苯-2-甲酸甲酯。Further preferably, the specific process of step A is: adding 2-bromo-4-nitrobenzoic acid methyl ester, 2-aminophenylboron and potassium carbonate into a mixed solution of DME and water in a volume ratio of 10:1 in a reaction vessel , stirred at room temperature for 30 min under the protection of nitrogen, then added the catalyst tetrakis(triphenylphosphine) palladium, stirred evenly under the protection of nitrogen, raised the temperature to 100°C and reacted until the reaction of the raw materials monitored by TLC was complete, evaporated the solvent under vacuum conditions, and the residue Add dichloromethane, wash twice with pure water, dry the organic phase over anhydrous sodium sulfate, evaporate the solvent, and then separate and purify by silica gel column chromatography to obtain 2'-amino-5-nitrobiphenyl-2- Methyl formate.
进一步优选,步骤B的具体过程为:在反应容器中将还原铁粉加入到冰乙酸中,升温至85℃后搅拌反应45min,在氮气保护下加入溶有2’-氨基-5-硝基联苯-2-甲酸甲酯的冰乙酸溶液,滴加完后于85℃继续反应直至TLC监控原料反应完全,然后通过硅藻土过滤反应液,硅藻土用热的冰乙酸进行洗涤,滤液在真空条件下蒸除反应溶剂,加入饱和碳酸氢钠,再用乙酸乙酯萃取反应液三次,合并有机相,有机相经无水硫酸钠干燥后蒸除溶剂,浓缩得到2’-氨基-5-胺基联苯-2-甲酸甲酯。More preferably, the specific process of step B is: add reduced iron powder to glacial acetic acid in a reaction vessel, heat up to 85°C and stir for 45 minutes to react, and add 2'-amino-5-nitrobisinated acid dissolved in nitrogen under the protection of nitrogen. The glacial acetic acid solution of methyl benzene-2-carboxylate, continue the reaction at 85°C after the dropwise addition until the raw materials are completely reacted by TLC, then filter the reaction solution through diatomaceous earth, the diatomite is washed with hot glacial acetic acid, and the filtrate is in The reaction solvent was evaporated under vacuum, saturated sodium bicarbonate was added, and the reaction solution was extracted three times with ethyl acetate, the organic phase was combined, the organic phase was dried over anhydrous sodium sulfate, the solvent was evaporated, and concentrated to obtain 2'-amino-5- Aminobiphenyl-2-carboxylic acid methyl ester.
进一步优选,步骤C的具体过程为:在反应容器中于0℃将2’-氨基-5-胺基联苯-2-甲酸甲酯加入到质量浓度为5%的稀硫酸中,搅拌滴加溶有催化剂亚硝酸钠的水溶液,滴加完后保持温度继续反应1h,再升温至60℃反应直至TLC监控原料反应完全,然后冷却至室温,用乙酸乙酯萃取反应液三次,合并有机相,有机相经无水硫酸钠干燥后蒸除溶剂,经硅胶柱层析分离提纯得到2’-氨基-5-羟基联苯-2-甲酸甲酯。Further preferably, the specific process of step C is: add 2'-amino-5-aminobiphenyl-2-carboxylic acid methyl ester to dilute sulfuric acid with a mass concentration of 5% in a reaction vessel at 0°C, stir and drop The aqueous solution in which the catalyst sodium nitrite was dissolved was added dropwise, and the temperature was kept to continue the reaction for 1 hour, and then the temperature was raised to 60° C. to react until the reaction of the raw materials was monitored by TLC, and then cooled to room temperature, and the reaction solution was extracted three times with ethyl acetate, and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, evaporated to remove the solvent, and separated and purified by silica gel column chromatography to obtain 2'-amino-5-hydroxybiphenyl-2-carboxylic acid methyl ester.
进一步优选,步骤D的具体过程为:在反应容器中将3-羟基甲苯与2-溴丙烷加入到无水处理的DMF中,再加入碳酸钾,升温至回流反应直至TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入到水中,再用二氯甲烷萃取水相三次,合并有机相后蒸除溶剂得到3-异丙氧基甲苯。Further preferably, the specific process of step D is: in the reaction vessel, 3-hydroxytoluene and 2-bromopropane are added to anhydrous DMF, then potassium carbonate is added, and the temperature is raised to reflux reaction until TLC monitors that the reaction of raw materials is complete. The solvent was distilled off under vacuum, the residue was added to water, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined and the solvent was distilled off to obtain 3-isopropoxytoluene.
进一步优选,步骤E的具体过程为:在反应容器中将3-异丙氧基甲苯加入到冰乙酸中,再加入定位催化剂铁粉,在室温条件下滴加溴素,30min滴加完,升温至40℃反应,再用300W钨灯照射反应,真空下蒸除溶剂冰乙酸,浓缩物中加入质量浓度为20%的氢氧化钠溶液,过滤反应液,滤液用二氯甲烷萃取三次,合并有机相,有机相再经过无水硫酸钠干燥后浓缩得到3-异丙氧基-6溴苄溴。Further preferably, the specific process of step E is: add 3-isopropoxytoluene to glacial acetic acid in a reaction vessel, then add iron powder as a positioning catalyst, add bromine dropwise at room temperature, finish adding dropwise in 30 minutes, and heat up React at 40°C, then irradiate the reaction with a 300W tungsten lamp, evaporate the solvent glacial acetic acid under vacuum, add sodium hydroxide solution with a mass concentration of 20% to the concentrate, filter the reaction solution, extract the filtrate three times with dichloromethane, and combine the organic phase, and the organic phase was dried over anhydrous sodium sulfate and then concentrated to obtain 3-isopropoxy-6 bromobenzyl bromide.
进一步优选,步骤F的具体过程为:在反应容器中将2’-氨基-5-羟基联苯-2-甲酸甲酯与3-异丙氧基-6-溴苄溴加入到干燥的丙酮中,再加入羟基氢活化催化剂钯/羟基磷灰石,加热至回流反应直至TLC监控原料反应完全,在真空条件下蒸除反应溶剂,浓缩物加入到二氯甲烷中,用纯净水洗涤有机相三次,分出有机相,在真空条件下蒸除溶剂后得到粗品,再经硅胶柱层析分离提纯得到5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯。Further preferably, the specific process of step F is: adding 2'-amino-5-hydroxybiphenyl-2-carboxylic acid methyl ester and 3-isopropoxy-6-bromobenzyl bromide to dry acetone in a reaction vessel , then add the hydroxyl hydrogen activation catalyst palladium/hydroxyapatite, heat to reflux reaction until TLC monitors the raw material reaction is complete, evaporate the reaction solvent under vacuum conditions, add the concentrate to dichloromethane, and wash the organic phase three times with pure water , separate the organic phase, evaporate the solvent under vacuum to obtain the crude product, then separate and purify by silica gel column chromatography to obtain 5-(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl- 2-Methyl carboxylate.
进一步优选,步骤G的具体过程为:在反应容器中将5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯与碳酸钾加入到二甲基乙酰胺中,在N2保护下加入苯环氢活化催化剂钯/羟基磷灰石,向反应体系中持续通入N2,同时排出N2,使其保持一个稳定流通环境,室温搅拌30min后密闭反应容器,再将反应容器放置在微波反应器中,加热到100℃反应直至TLC监控原料反应完全,然后从微波反应器中取出反应容器加入纯净水淬灭反应,再用乙酸乙酯萃取反应液三次,合并有机相,用无水硫酸钠干燥后蒸除溶剂,最后经硅胶柱层析分离提纯得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯。Further preferably, the specific process of step G is: in a reaction vessel, 5-(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl-2-formic acid methyl ester and potassium carbonate are added to di In methylacetamide, add benzene ring hydrogen activation catalyst palladium/hydroxyapatite under the protection of N2 , continuously feed N2 into the reaction system, and discharge N2 at the same time to maintain a stable circulation environment, and stir at room temperature for 30 minutes Finally, seal the reaction vessel, then place the reaction vessel in a microwave reactor, heat it to 100°C and react until the raw materials are completely reacted as monitored by TLC, then take out the reaction vessel from the microwave reactor and add pure water to quench the reaction, then extract with ethyl acetate The reaction solution was three times, and the organic phase was combined, dried with anhydrous sodium sulfate, evaporated to remove the solvent, and finally separated and purified by silica gel column chromatography to obtain 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyridine Methyl pyran-2-carboxylate.
进一步优选,步骤H的具体过程为:在反应容器中将3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯加入到乙醇中,再加入溶有氢氧化钠的水溶液,升温至70℃反应直至TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入到水中,再用乙酸乙酯洗涤水相三次,水相用稀盐酸溶解调节pH为3,再用二氯甲烷萃取水相三次,合并有机相,最后蒸除溶剂后得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸。Further preferably, the specific process of step H is: adding 3-(2-aminophenyl)-8-isopropoxyl-6H-dibenzopyran-2-carboxylic acid methyl ester to ethanol in a reaction vessel, and then Add an aqueous solution dissolved in sodium hydroxide, raise the temperature to 70°C and react until the reaction of the raw materials is monitored by TLC, evaporate the solvent under vacuum, add the residue to water, wash the water phase with ethyl acetate three times, and wash the water phase with dilute hydrochloric acid Dissolve and adjust the pH to 3, then extract the aqueous phase three times with dichloromethane, combine the organic phases, and finally evaporate the solvent to obtain 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran- 2-Formic acid.
进一步优选,步骤I的具体过程为:在反应容器中将3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸加入到无水THF中,反应温度降低至-60℃,滴加氢化铝锂的四氢呋喃溶液,保持温度继续反应2h,再升温至0℃反应2h,加入冰水淬灭反应,抽滤反应液,滤液用乙酸乙酯萃取多次,合并有机相,蒸除溶剂后得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇。Further preferably, the specific process of step I is: 3-(2-aminophenyl)-8-isopropoxyl-6H-dibenzopyran-2-carboxylic acid is added to anhydrous THF in a reaction vessel, and the reaction Lower the temperature to -60°C, add lithium aluminum hydride tetrahydrofuran solution dropwise, keep the temperature and continue the reaction for 2h, then raise the temperature to 0°C for 2h, add ice water to quench the reaction, filter the reaction solution with suction, and extract the filtrate with ethyl acetate. The second time, the organic phases were combined, and the solvent was distilled off to obtain 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methanol.
进一步优选,步骤J的具体过程为:在反应容器中将3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇、对甲基磺酰氯和碳酸钾加入到DMF中,升温至80℃反应直至TLC监控原料反应完全,加入纯净水淬灭反应,再用乙酸乙酯萃取三次,合并有机相,有机相经无水硫酸钠干燥后蒸除溶剂,再经硅胶柱层析分离提纯得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯。Further preferably, the specific process of step J is: in a reaction vessel, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methanol, p-methylsulfonyl chloride and carbonic acid Potassium was added to DMF, and the temperature was raised to 80°C to react until the reaction of raw materials monitored by TLC was complete. Then, pure water was added to quench the reaction, and then extracted three times with ethyl acetate, and the organic phase was combined. The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated. After separation and purification by silica gel column chromatography, 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methyl p-methylsulfonate was obtained.
进一步优选,步骤K的具体过程为:在反应容器中将3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯加入到乙腈中,再加入苯胺,机械搅拌并升温至70℃反应直至TLC监控原料反应完全,减压蒸出溶剂乙腈,再加入正己烷,冷却至-5℃,搅拌过程中有固体析出,过滤反应液得到固体,并用冷甲苯洗涤,滤饼烘干后得到8-异丙氧基-6H-二苯并吡喃并苯基并哌啶并苯。Further preferably, the specific process of step K is: add 3-(2-aminobenzene)-8-isopropoxyl-6H-dibenzopyran-2-methyl p-methylsulfonate in the reaction vessel Add aniline to acetonitrile, stir mechanically and heat up to 70°C until TLC monitors that the reaction of raw materials is complete, distill off the solvent acetonitrile under reduced pressure, then add n-hexane, cool to -5°C, solids precipitate during stirring, filter the reaction The liquid was obtained as a solid, which was washed with cold toluene, and the filter cake was dried to obtain 8-isopropoxy-6H-dibenzopyranophenylpiperidoacene.
进一步优选,步骤L的具体过程为:在反应容器中将8-异丙氧基-6H-二苯并吡喃并苯基并哌啶并苯加入到二氯甲烷中,再加入溴化锂,于0℃搅拌反应直至TLC监控原料反应完全,蒸除反应溶剂得到8-羟基-6H-二苯并吡喃并六氢吡啶并苯。Further preferably, the specific process of step L is: add 8-isopropoxy-6H-dibenzopyranophenylpiperidocene into dichloromethane in a reaction vessel, then add lithium bromide, and The reaction was stirred at °C until the reaction of the raw materials was monitored by TLC, and the reaction solvent was distilled off to obtain 8-hydroxy-6H-dibenzopyrano-hexahydropyridocene.
进一步优选,步骤M的具体过程为:在反应容器中将8-羟基-6H-二苯并吡喃并六氢吡啶并苯与三乙胺加入无水处理的二氯甲烷中,于0℃滴加三氟甲磺酸酐,滴加完后升温至室温直至TLC监控原料反应完全,蒸除反应溶剂,剩余物中加入正己烷,于0℃搅拌析晶,有黄色固体出现,抽滤烘干后得到8-三氟甲磺酸酯基-6H-二苯并吡喃并六氢吡啶并苯。Further preferably, the specific process of step M is: add 8-hydroxy-6H-dichromenhexahydropyridocene and triethylamine into anhydrous dichloromethane in a reaction vessel, and drop Add trifluoromethanesulfonic anhydride, after the dropwise addition, raise the temperature to room temperature until the reaction of the raw materials monitored by TLC is complete, evaporate the reaction solvent, add n-hexane to the residue, stir and crystallize at 0°C, a yellow solid appears, filter and dry 8-Trifluoromethanesulfonate-6H-dibenzopyranohexahydropyridocene is obtained.
进一步优选,步骤N的具体过程为:在高压反应釜中将8-三氟甲磺酸酯基-6H-二苯并吡喃并六氢吡啶并苯、苯胺和三乙胺加入到无水处理后的DMF中,再加入催化剂1,3-双(二苯基膦)丙烷,在氮气保护下于室温搅拌后加入雷尼镍,再将反应体系抽真空,排出氮气,通入一氧化碳,使反应压强达到0.2MPa,升温至60℃反应直至TLC监控原料反应完全,降至室温,排除未反应完的一氧化碳,过滤反应液,减压蒸除溶剂DMF,向剩余物中加入甲苯,于0℃搅拌有淡黄色固体析出,抽滤固体,烘干后得到N-8-苯胺基-6H-二苯并吡喃并六氢吡啶并苯。Further preferably, the specific process of step N is: adding 8-trifluoromethanesulfonate group-6H-dibenzopyrano-hexahydropyridocene, aniline and triethylamine to anhydrous treatment in an autoclave In the final DMF, add the catalyst 1,3-bis(diphenylphosphine)propane, add Raney nickel after stirring at room temperature under the protection of nitrogen, then vacuumize the reaction system, discharge nitrogen, and introduce carbon monoxide to make the reaction The pressure reached 0.2MPa, and the temperature was raised to 60°C to react until the raw materials were completely reacted under TLC monitoring, then cooled to room temperature, and unreacted carbon monoxide was removed, the reaction liquid was filtered, the solvent DMF was evaporated under reduced pressure, toluene was added to the residue, and stirred at 0°C A light yellow solid was precipitated, and the solid was filtered with suction and dried to obtain N-8-anilino-6H-dibenzopyrano-hexahydropyrido-acene.
本发明所述的一种具有6H-二苯并吡喃结构化合物的合成路线为:A synthetic route of a compound having a 6H-dibenzopyran structure described in the present invention is:
。 .
本发明合成工艺简单且成本低廉,经过活性测试可知制得的FSH拮抗剂药物分子对FSH受体的作用效果较好,有望进一步推广应用。The synthesis process of the invention is simple and the cost is low, and the activity test shows that the prepared FSH antagonist drug molecule has a good effect on the FSH receptor, and it is expected to be further popularized and applied.
具体实施方式detailed description
以下通过实施例对本发明的上述内容做进一步详细说明,但不应该将此理解为本发明上述主题的范围仅限于以下的实施例,凡基于本发明上述内容实现的技术均属于本发明的范围。The above-mentioned contents of the present invention are described in further detail below through the embodiments, but this should not be interpreted as the scope of the above-mentioned themes of the present invention being limited to the following embodiments, and all technologies realized based on the above-mentioned contents of the present invention all belong to the scope of the present invention.
实施例1Example 1
在反应瓶中,把2-溴-4-硝基苯甲酸甲酯5.0g、2-氨基苯硼酸4.0g和碳酸钾5g加入到体积比为10:1的DME与水的混合溶液120mL中,氮气保护下室温搅拌30min,再加入催化剂四(三苯基膦)钯1g,在氮气保护下搅拌均匀,缓慢升温至100℃,反应14h后TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入二氯甲烷中,再用纯净水50mL洗涤两次,有机相经无水硫酸钠干燥后蒸除溶剂,再经硅胶柱层析分离提纯得到2’-胺基-5-硝基联苯-2-甲酸甲酯4.9g;1H NMR (400 MHz, DMSO-d6) δ: 8.34 (s, 1 H), 8.17(d, J=2.4Hz, 1 H),7.97 (d, J=8.6Hz,1 H), 7.62-7.57 (m, 2 H), 7.33-7.30(m, 2 H), 6.25(s, 2H),3.79 (s, 3 H)。In the reaction flask, 5.0 g of methyl 2-bromo-4-nitrobenzoate, 4.0 g of 2-aminophenylboronic acid and 5 g of potassium carbonate were added into 120 mL of a mixed solution of DME and water at a volume ratio of 10:1, Stir at room temperature for 30 min under the protection of nitrogen, then add catalyst tetrakis (triphenylphosphine) palladium 1g, stir evenly under the protection of nitrogen, slowly heat up to 100 ° C, after 14 hours of reaction, TLC monitors the complete reaction of the raw materials, and evaporates the solvent under vacuum conditions. The residue was added to dichloromethane, washed twice with 50 mL of pure water, the organic phase was dried over anhydrous sodium sulfate, the solvent was evaporated, and then separated and purified by silica gel column chromatography to obtain 2'-amino-5-nitrobi Benzene-2-carboxylic acid methyl ester 4.9g; 1 H NMR (400 MHz, DMSO-d6) δ: 8.34 (s, 1 H), 8.17(d, J=2.4Hz, 1 H),7.97 (d, J= 8.6Hz, 1H), 7.62-7.57 (m, 2H), 7.33-7.30(m, 2H), 6.25(s, 2H), 3.79 (s, 3H).
实施例2Example 2
在反应瓶中,把还原铁粉5g加入到冰乙酸70mL中,升温至85℃后搅拌反应45min,在氮气保护下缓慢加入溶有2’-氨基-5-硝基联苯-2-甲酸甲酯6g的冰乙酸溶液70mL,滴加完后在85℃条件下继续反应2h,TLC监控原料反应完全后通过硅藻土进行过滤反应液,硅藻土用一定量的热的冰乙酸进行洗涤,滤液在真空条件下蒸除反应溶剂,加入一定量的饱和碳酸氢钠,再用乙酸乙酯萃取反应液三次,合并有机相,有机相经无水硫酸钠干燥后蒸除溶剂,浓缩得到2’-氨基-5-氨基联苯-2-甲酸甲酯5.1g;1H NMR (400 MHz, CDCl3) δ: 7.97 (s,1 H), 7.71-7.69 (m, 1 H), 7.35 (s, 2 H), 7.23-7.21 (m, 1 H), 6.67-6.61(m,4H), 6.44-6.39 (m, 3 H), 6.21 (s, 1 H), 6.07(s, 1H), 5.93-5.90 (m, 2 H), 3.27(s, 3 H)。In the reaction flask, add 5g of reduced iron powder into 70mL of glacial acetic acid, raise the temperature to 85°C and stir for 45min, then slowly add the solution of 2'-amino-5-nitrobiphenyl-2-formic acid under the protection of nitrogen. 70mL of glacial acetic acid solution of 6g of ester, after the dropwise addition, continue to react at 85°C for 2h, monitor the raw material reaction by TLC, filter the reaction solution through diatomaceous earth, wash the diatomite with a certain amount of hot glacial acetic acid, The filtrate was evaporated to remove the reaction solvent under vacuum conditions, a certain amount of saturated sodium bicarbonate was added, and the reaction solution was extracted three times with ethyl acetate, the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, the solvent was evaporated, and concentrated to obtain 2' -Amino-5-aminobiphenyl-2-methyl carboxylate 5.1g; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.97 (s,1 H), 7.71-7.69 (m, 1 H), 7.35 (s , 2 H), 7.23-7.21 (m, 1 H), 6.67-6.61(m,4H), 6.44-6.39 (m, 3 H), 6.21 (s, 1 H), 6.07(s, 1H), 5.93 -5.90 (m, 2H), 3.27(s, 3H).
实施例3Example 3
在反应瓶中,在温度为0℃条件下,把2’-氨基-5-胺基联苯-2-甲酸甲酯5.0g加入到质量浓度为5%的稀硫酸 100mL中,搅拌10min后,再缓慢滴加溶有亚硝酸钠2.0g的水溶液20mL,滴加完后保持温度继续反应1h,再缓慢升温至60℃反应8h,TLC监控原料反应完全后冷却至室温,用乙酸乙酯萃取反应液三次,合并有机相,有机相经无水硫酸钠干燥后蒸除溶剂,经硅胶柱层析分离提纯得到2’-氨基-5-羟基联苯-2-甲酸甲酯3.9g;1H NMR (400 MHz,CDCl3) δ: 7.94 (d, J=12.0Hz, 1 H), 7.54-7.49 (m, 2H), 7.16 (d, J=12.0Hz, 1H), 6.92-6.91 (m, 3 H), 6.27 (s, 2 H), 5.35(s, 1H), 3.25 (s, 3 H)。In the reaction flask, at a temperature of 0°C, add 5.0 g of 2'-amino-5-aminobiphenyl-2-carboxylic acid methyl ester into 100 mL of dilute sulfuric acid with a mass concentration of 5%, and stir for 10 min. Slowly add 20 mL of an aqueous solution dissolved with 2.0 g of sodium nitrite dropwise. After the dropwise addition, keep the temperature and continue the reaction for 1 hour, then slowly raise the temperature to 60°C and react for 8 hours. After TLC monitors the complete reaction of the raw materials, cool to room temperature and extract the reaction with ethyl acetate. liquid three times, combined the organic phase, the organic phase was dried over anhydrous sodium sulfate, evaporated to remove the solvent, separated and purified by silica gel column chromatography to obtain 3.9 g of 2'-amino-5-hydroxybiphenyl-2-carboxylic acid methyl ester; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.94 (d, J=12.0Hz, 1 H), 7.54-7.49 (m, 2H), 7.16 (d, J=12.0Hz, 1H), 6.92-6.91 (m, 3 H), 6.27(s, 2H), 5.35(s, 1H), 3.25(s, 3H).
实施例4Example 4
在反应瓶中,把3-羟基甲苯10g和2-溴丙烷10g加入到无水处理的DMF 100mL中,再加入碳酸钾15g,缓慢升温至回流反应24h,TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入到水中,再用二氯甲烷萃取水相三次,合并有机相,最后蒸除溶剂后得到产品3-异丙氧基甲苯13g;1H NMR (400 MHz, CDCl3) δ: 7.33 (s, 1H), 7.17-7.12(m, 3H), 4.73-4.71 (m, 1H), 2.61 (s, 3 H), 1.34 (d, J=8.0Hz, 6 H)。In a reaction flask, add 10 g of 3-hydroxytoluene and 10 g of 2-bromopropane to 100 mL of anhydrous DMF, then add 15 g of potassium carbonate, and slowly raise the temperature to reflux for 24 hours. TLC monitors that the reaction of the raw materials is complete. The solvent was evaporated, the residue was added to water, and the aqueous phase was extracted three times with dichloromethane, the organic phases were combined, and the solvent was finally evaporated to obtain 13 g of the product 3-isopropoxytoluene; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.33 (s, 1H), 7.17-7.12(m, 3H), 4.73-4.71 (m, 1H), 2.61 (s, 3H), 1.34 (d, J=8.0Hz, 6H).
实施例5Example 5
在反应瓶中,把3-异丙氧基甲苯15g加入到冰乙酸100mL中,再加入定位催化剂铁粉3g,在室温条件下缓慢滴加溴素8mL,约30min滴加完,升温至40℃后反应10h,再用300W钨灯照射反应5h,真空下蒸除溶剂冰乙酸,浓缩物中加入一定量的质量浓度为20%的氢氧化钠溶液,过滤反应液,滤液用二氯甲烷萃取三次,合并有机相,有机相再经过无水硫酸钠干燥后浓缩得到3-异丙氧基-6-溴苄溴23g;1H NMR (400 MHz, CDCl3) δ: 7.50-7.49 (m, 1H),7.06-7.04 (m, 2H), 4.69 (s, 2H), 4.29-4.27(m, 1H), 1.37 (d, J=8.0Hz, 6 H)。In the reaction flask, add 15g of 3-isopropoxytoluene to 100mL of glacial acetic acid, then add 3g of iron powder as a positioning catalyst, slowly add 8mL of bromine dropwise at room temperature, the dropwise addition is completed in about 30 minutes, and the temperature is raised to 40°C After reacting for 10 hours, irradiate the reaction with 300W tungsten lamp for 5 hours, evaporate the solvent glacial acetic acid under vacuum, add a certain amount of sodium hydroxide solution with a mass concentration of 20% in the concentrate, filter the reaction solution, and extract the filtrate three times with dichloromethane , the organic phases were combined, and the organic phase was dried over anhydrous sodium sulfate and then concentrated to obtain 23 g of 3-isopropoxy-6-bromobenzyl bromide; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.50-7.49 (m, 1H ), 7.06-7.04 (m, 2H), 4.69 (s, 2H), 4.29-4.27(m, 1H), 1.37 (d, J=8.0Hz, 6H).
实施例6Example 6
在反应瓶中加入二氯化钯5g,再加入质量比为1:1的甲醇-水混合溶液250mL,再加入羧甲基纤维素钠1g,用碳酸钠调节体系的pH为4.5,加入羟基磷灰石50g,在室温下搅拌2h后放入高压釜中,在100KPa,100℃条件下搅拌加氢还原反应2h,减压抽滤,去离子水洗至中性且经硝酸银溶液检测无氯离子,在常压60℃条件下干燥3h得到钯/羟基磷灰石40g。Add 5g of palladium dichloride to the reaction flask, then add 250mL of methanol-water mixed solution with a mass ratio of 1:1, then add 1g of sodium carboxymethylcellulose, adjust the pH of the system to 4.5 with sodium carbonate, add hydroxyphosphorus Limestone 50g, stirred at room temperature for 2h, put into autoclave, stirred at 100KPa, 100°C for hydrogenation reduction reaction for 2h, filtered under reduced pressure, washed with deionized water until neutral and detected by silver nitrate solution to be free of chloride ions , and dried under normal pressure at 60° C. for 3 hours to obtain 40 g of palladium/hydroxyapatite.
实施例7Example 7
在反应瓶中,把2’-氨基-5-羟基联苯-2-甲酸甲酯5g和3-异丙氧基-6-溴苄溴8g加入到干燥的丙酮250mL中,再加入羟基氢活化催化剂钯/羟基磷灰石0.5g,加热至回流反应4h,TLC监控原料反应完全,在真空条件下蒸除反应溶剂,浓缩物加入到二氯甲烷中,再用纯净水洗涤有机相三次,分出有机相,在真空条件下蒸除溶剂后得到产品粗品,再经硅胶柱层析分离提纯得到5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯7.1g;1H NMR (400MHz, CDCl3) δ: 7.94 (d, J=8.0 Hz, 1H), 7.47-7.41(m, 1H), 7.40 (s, 1H), 7.34-7.18 (m, 5H), 7.03 (s, 1H), 5.18 (s, 2H), 4.61-4.53(m, 1H), 3.81 (s, 3 H),3.62 (s, 3H), 1.28 (d, J=8.0Hz, 6 H)。In a reaction flask, add 5 g of 2'-amino-5-hydroxybiphenyl-2-methyl carboxylate and 8 g of 3-isopropoxy-6-bromobenzyl bromide into 250 mL of dry acetone, and then add hydroxyl hydrogen to activate Catalyst palladium/hydroxyapatite 0.5g, heated to reflux reaction for 4h, TLC monitors raw material reaction is complete, evaporates the reaction solvent under vacuum condition, joins in dichloromethane concentrate, washes organic phase three times with pure water again, separates The organic phase was taken out, and the crude product was obtained after distilling off the solvent under vacuum conditions, and then separated and purified by silica gel column chromatography to obtain 5-(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl-2 -Methyl formate 7.1g; 1 H NMR (400MHz, CDCl 3 ) δ: 7.94 (d, J=8.0 Hz, 1H), 7.47-7.41(m, 1H), 7.40 (s, 1H), 7.34-7.18 ( m, 5H), 7.03 (s, 1H), 5.18 (s, 2H), 4.61-4.53(m, 1H), 3.81 (s, 3H), 3.62 (s, 3H), 1.28 (d, J=8.0 Hz, 6H).
实施例8Example 8
在反应瓶中,把5-(2-溴-5-异丙氧基苯甲醇)-2’-氨基联苯-2-甲酸甲酯10g和碳酸钾5g加入二甲基乙酰胺100mL中,在N2保护下加入苯环氢活化催化剂钯/羟基磷灰石1g,往反应体系中不停通入N2,同时排出N2,使其保持一个稳定流通环境,室温搅拌30min后密闭反应瓶,把其放置在微波反应器中,加热到100℃反应24h,TLC监控原料反应完全,从微波反应器中拿出反应瓶,加入一定量的纯净水淬灭反应,再用乙酸乙酯萃取反应液三次,合并有机相,再用无水硫酸钠干燥后蒸除溶剂,最后经硅胶柱层析分离提纯得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯7.5g;1H NMR (400 MHz, CDCl3) δ: 8.12 (d, J=8.0Hz, 1H), 7.71-7.65(m, 4H), 7.43-7.41 (m, 2H), 7.16-7.12 (m, 2H), 6.27(s, 2H),5.16 (s, 2H), 4.72(d, J=8.0Hz, 1H), 3.47 (s, 3H), 1.25-1.23 (m, 6 H)。In a reaction flask, add 10 g of 5-(2-bromo-5-isopropoxybenzyl alcohol)-2'-aminobiphenyl-2-formic acid methyl ester and 5 g of potassium carbonate into 100 mL of dimethylacetamide. Add 1 g of benzene ring hydrogen activation catalyst palladium/hydroxyapatite under the protection of N 2 , continuously feed N 2 into the reaction system, and discharge N 2 at the same time to maintain a stable circulation environment, and seal the reaction bottle after stirring at room temperature for 30 minutes. Place it in a microwave reactor, heat it to 100°C and react for 24 hours. TLC monitors the complete reaction of the raw materials. Take out the reaction bottle from the microwave reactor, add a certain amount of pure water to quench the reaction, and then extract the reaction solution with ethyl acetate. Three times, the organic phases were combined, dried with anhydrous sodium sulfate, evaporated to remove the solvent, and finally separated and purified by silica gel column chromatography to obtain 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran -Methyl 2-carboxylate 7.5g; 1 H NMR (400 MHz, CDCl 3 ) δ: 8.12 (d, J=8.0Hz, 1H), 7.71-7.65(m, 4H), 7.43-7.41 (m, 2H) , 7.16-7.12 (m, 2H), 6.27(s, 2H),5.16 (s, 2H), 4.72(d, J=8.0Hz, 1H), 3.47 (s, 3H), 1.25-1.23 (m, 6 h).
实施例9Example 9
在反应瓶中,把3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸甲酯5g加入到乙醇20mL中,再加入溶有氢氧化钠2.5g的水溶液10mL,升温至70℃反应1h,TLC监控原料反应完全,在真空条件下蒸除溶剂,剩余物加入到水中,再用乙酸乙酯洗涤水相三次,水相再用稀盐酸溶解调节pH为3,再用二氯甲烷萃取水相三次,合并有机相,最后蒸除溶剂后得到产品3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸4.1g;1H NMR (400 MHz, CDCl3) δ:7.96-7.95 (m, 1H), 7.69-7.65(m, 4H), 7.39-7.37 (m, 2H), 7.12-7.10 (m, 2H),6.26(s, 2H), 5.16 (s, 2H), 4.72(d, J=8.0Hz, 1H), 1.21-1.19 (m, 6 H)。In the reaction flask, add 5 g of 3-(2-aminophenyl)-8-isopropoxy-6H-dibenzopyran-2-carboxylic acid methyl ester into 20 mL of ethanol, and then add 2.5 mL of dissolved sodium hydroxide 10 mL of aqueous solution of g, heated to 70°C and reacted for 1 h, TLC monitored the complete reaction of the raw materials, evaporated the solvent under vacuum, added the residue into water, washed the water phase with ethyl acetate three times, and dissolved the water phase with dilute hydrochloric acid to adjust The pH is 3, and the aqueous phase is extracted three times with dichloromethane, the organic phases are combined, and the solvent is finally evaporated to obtain the product 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2 -Formic acid 4.1g; 1 H NMR (400 MHz, CDCl 3 ) δ:7.96-7.95 (m, 1H), 7.69-7.65(m, 4H), 7.39-7.37 (m, 2H), 7.12-7.10 (m, 2H), 6.26(s, 2H), 5.16 (s, 2H), 4.72(d, J=8.0Hz, 1H), 1.21-1.19 (m, 6H).
实施例10Example 10
反应瓶中,把3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲酸10g加入到无水THF200mL中,反应温度降低至-60℃,缓慢滴加氢化铝锂的四氢呋喃溶液30mL,保持温度继续反应2h,再缓慢升温至0℃,反应2h,加入一定量的冰水淬灭反应,抽滤反应液,滤液用乙酸乙酯萃取多次,合并有机相,蒸除溶剂后得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇7.7g;1H NMR (400 MHz, CDCl3) δ: 7.87-7.69 (m, 4H), 7.61-7.55(m, 2H), 7.12-7.10 (m, 3H), 6.27(s, 2H), 4.70 (s, 2H), 4.39(s, 2H), 3.65(s, 1H), 1.23 (s, 6H)。In the reaction flask, add 10 g of 3-(2-aminophenyl)-8-isopropoxy-6H-dibenzopyran-2-carboxylic acid into 200 mL of anhydrous THF, lower the reaction temperature to -60°C, and slowly drop Add 30 mL of tetrahydrofuran solution of lithium aluminum hydride, keep the temperature and continue to react for 2 hours, then slowly raise the temperature to 0°C, react for 2 hours, add a certain amount of ice water to quench the reaction, filter the reaction solution with suction, and extract the filtrate with ethyl acetate several times, The organic phases were combined, and the solvent was evaporated to obtain 7.7 g of 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methanol; 1 H NMR (400 MHz, CDCl 3 ) δ : 7.87-7.69 (m, 4H), 7.61-7.55(m, 2H), 7.12-7.10 (m, 3H), 6.27(s, 2H), 4.70 (s, 2H), 4.39(s, 2H), 3.65 (s, 1H), 1.23 (s, 6H).
实施例11Example 11
在反应瓶中,把3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲醇10g、对甲基磺酰氯5g和碳酸钾20g加入到DMF中,缓慢升温至80℃,反应8h后TLC监控原料反应完全,加入一定量的纯净水淬灭反应,再用乙酸乙酯50mL萃取三次,合并有机相,有机相经无水硫酸钠30g干燥后蒸除溶剂得到3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯8.4g;1H NMR (400 MHz, CDCl3) δ: 7.87-7.69 (m, 4H), 7.61-7.55(m, 2H), 7.12-7.10(m, 3H), 6.27(s, 2H), 4.70 (s, 2H), 4.39(s, 2H), 3.16(s, 3H), 1.23 (s, 6 H)。In a reaction flask, 10 g of 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methanol, 5 g of p-methylsulfonyl chloride and 20 g of potassium carbonate were added to DMF, Slowly raise the temperature to 80°C. After reacting for 8 hours, TLC monitors the complete reaction of the raw materials. Add a certain amount of pure water to quench the reaction, then extract three times with 50 mL of ethyl acetate, combine the organic phase, dry the organic phase with 30 g of anhydrous sodium sulfate, and evaporate The solvent was used to obtain 8.4 g of 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methyl p-methylsulfonate; 1 H NMR (400 MHz, CDCl 3 ) δ : 7.87-7.69 (m, 4H), 7.61-7.55(m, 2H), 7.12-7.10(m, 3H), 6.27(s, 2H), 4.70 (s, 2H), 4.39(s, 2H), 3.16 (s, 3H), 1.23 (s, 6H).
实施例12Example 12
反应瓶中,把3-(2-氨基苯)-8-异丙氧基-6H-二苯并吡喃-2-甲基对甲基磺酸酯10g加入到乙腈150mL中,再加入苯胺10g,机械搅拌并加热至70℃,反应10h后经TLC监控[展开剂:PE:EA=7:1]原料反应完全,减压蒸出溶剂乙腈,再加入一定量的正己烷700mL,冷却至-5℃,搅拌过程中逐渐有大量固体析出,过滤反应液得到固体,并用一定量的冷甲苯200mL洗涤,滤饼烘干后得到8-异丙氧基-6H-二苯并吡喃并苯基并哌啶并苯9.3g;1H NMR (400 MHz,CDCl3) δ: 7.75(d, J=8.0Hz, 1H), 7.62(s, 1H), 7.57(s, 1H), 7.21-7.19(m, 2H),7.03-7.02 (m, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H),1.21 (d, J=8.0Hz, 6 H)。In the reaction flask, add 10 g of 3-(2-aminobenzene)-8-isopropoxy-6H-dibenzopyran-2-methyl p-methylsulfonate into 150 mL of acetonitrile, then add 10 g of aniline , stirred mechanically and heated to 70°C, and monitored by TLC after 10 hours of reaction [developing agent: PE:EA=7:1] The raw materials were completely reacted, the solvent acetonitrile was distilled off under reduced pressure, and then a certain amount of n-hexane 700mL was added, cooled to - 5°C, a large amount of solids gradually precipitated during the stirring process, the reaction solution was filtered to obtain solids, and washed with a certain amount of cold toluene 200mL, and the filter cake was dried to obtain 8-isopropoxy-6H-dibenzopyranophenyl Piperidoacene 9.3g; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.75(d, J=8.0Hz, 1H), 7.62(s, 1H), 7.57(s, 1H), 7.21-7.19( m, 2H), 7.03-7.02 (m, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H), 1.21 (d, J= 8.0Hz, 6H).
实施例13Example 13
在反应瓶中,把8-异丙氧基-6H-二苯并吡喃并苯基并哌啶并苯15g加入到二氯甲烷300mL中,再加入溴化锂10g,在0℃条件下搅拌2h,TLC监控原料反应完全后,蒸除反应溶剂得到8-羟基-6H-二苯并吡喃并六氢吡啶并苯;1H NMR (400 MHz, CDCl3) δ: 7.75(d, J=8.0Hz, 1H), 7.62(s, 1H), 7.57(s, 1H), 7.21-7.19(m, 2H), 7.03-7.02 (m, 1H),5.36(s, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H)。In a reaction flask, add 15 g of 8-isopropoxy-6H-dibenzopyranophenylpiperidocene into 300 mL of dichloromethane, then add 10 g of lithium bromide, and stir at 0°C for 2 h. After TLC monitors the complete reaction of the raw materials, the reaction solvent is evaporated to obtain 8-hydroxy-6H-dibenzopyrano-hexahydropyridocene; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.75(d, J=8.0Hz , 1H), 7.62(s, 1H), 7.57(s, 1H), 7.21-7.19(m, 2H), 7.03-7.02 (m, 1H), 5.36(s, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H).
实施例14Example 14
在反应瓶中,把8-羟基-6H-二苯并吡喃并六氢吡啶并苯10g和三乙胺15g加入无水处理的二氯甲烷300mL中,反应系统温度设定为0℃,缓慢滴加三氟甲磺酸酐30g,滴加完后升至室温反应2h,TLC监控原料反应完全,蒸除反应溶剂,剩余物中加入正己烷,于0℃搅拌析晶,有大量黄色固体出现,抽滤烘干后得到8-TfO基-6H-二苯并吡喃并六氢吡啶并苯;1H NMR(400 MHz, CDCl3) δ: 7.75-7.72(m, 2H), 7.57(s, 1H), 7.21-7.19(m, 2H), 7.03-7.02 (m, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H)。In a reaction flask, add 10 g of 8-hydroxy-6H-dibenzohexahydropyridocene and 15 g of triethylamine into 300 mL of anhydrous dichloromethane, set the temperature of the reaction system to 0°C, and slowly Add 30 g of trifluoromethanesulfonic anhydride dropwise, and after the dropwise addition, rise to room temperature and react for 2 hours. TLC monitors the complete reaction of the raw materials, evaporates the reaction solvent, adds n-hexane to the residue, stirs and crystallizes at 0°C, and a large amount of yellow solid appears. After suction filtration and drying, 8-TfO-6H-dibenzopyrano-hexahydropyridobenzene was obtained; 1 H NMR (400 MHz, CDCl 3 ) δ: 7.75-7.72(m, 2H), 7.57(s, 1H), 7.21-7.19(m, 2H), 7.03-7.02 (m, 1H), 5.27 (s, 1H), 5.15-5.13(m, 2H), 4.69(s, 1H), 4.27(s, 2H) .
实施例15Example 15
在高压反应釜中,把8-TfO基-6H-二苯并吡喃并六氢吡啶并苯10g、苯胺5g和三乙胺5g加入无水处理后的DMF中,再加入催化剂1,3-双(二苯基膦)丙烷1g,在氮气保护下,室温搅拌2h后加入雷尼镍1g,把反应体系抽真空,排出氮气,通入一氧化碳,使反应压强达到0.2MPa,缓慢升温至60℃,TLC监控原料反应完全,缓慢降至室温,排除未反应完的一氧化碳,过滤反应液,减压蒸除溶剂DMF,向剩余物中加入甲苯,于0℃搅拌有大量淡黄色固体析出,抽滤固体,烘干后得到N-8-苯胺基-6H-二苯并吡喃并六氢吡啶并苯;1H NMR (400 MHz,CDCl3) δ: 9.17(s, 1H), 8.06-7.97(m, 4H), 7.59-7.54(m, 4H), 7.21-7.19(m, 2H),7.03-7.00 (m, 3H), 5.33 (s, 1H), 5.15-5.13(m, 2H), 4.26(s, 2H)。In a high-pressure reactor, add 10 g of 8-TfO-6H-dibenzopyrano-hexahydropyridocene, 5 g of aniline and 5 g of triethylamine into DMF after anhydrous treatment, and then add the catalyst 1,3- Add 1 g of bis(diphenylphosphine) propane, under the protection of nitrogen, stir at room temperature for 2 hours, then add 1 g of Raney nickel, vacuumize the reaction system, discharge nitrogen, feed carbon monoxide, make the reaction pressure reach 0.2 MPa, and slowly raise the temperature to 60°C , TLC monitors the complete reaction of the raw material, slowly lowers to room temperature, removes unreacted carbon monoxide, filters the reaction solution, evaporates the solvent DMF under reduced pressure, adds toluene to the residue, stirs at 0°C, a large amount of light yellow solid precipitates, and suction filters Solid, N-8-anilino-6H-dibenzopyrano-hexahydropyridocene was obtained after drying; 1 H NMR (400 MHz, CDCl 3 ) δ: 9.17(s, 1H), 8.06-7.97( m, 4H), 7.59-7.54(m, 4H), 7.21-7.19(m, 2H),7.03-7.00 (m, 3H), 5.33 (s, 1H), 5.15-5.13(m, 2H), 4.26( s, 2H).
实施例15Example 15
抗肿瘤活性测试Antitumor activity test
收集生长期前列腺癌细胞DU145,以MTS法测定一下化合物的抗癌活性,将细胞以适当浓度(每毫升4×104个细胞)加到96孔细胞培养板中(含10%胎小牛血清得培养液配成单个细胞悬液),培养24小时后,在37℃、体积浓度为5%的CO2条件下与不同浓度的化合物作用72小时,然后将MTS(最终质量浓度2mg/mL)和DMS(最终摩尔浓度30μM)的混合物直接加入含细胞的培养基中,继续置培养箱孵育4h。作用4h后,弃去上清液,每孔加入150μLDMSO,振荡,细胞存活率通过其对MTS作用的代谢物在酶联免疫监测仪490nm波长下的吸收率测定,FSHR拮抗剂药物分子对该细胞的抑制率IC50为3.7μmol·L-1,初步生物活性测试表明,该化合物在前列腺癌细胞DU145中对癌细胞有一定抑制作用。Collect growth phase prostate cancer cells DU145, and use the MTS method to measure the anticancer activity of the compound, and add the cells at an appropriate concentration (4×10 4 cells per milliliter) to a 96-well cell culture plate (containing 10% fetal calf serum After 24 hours of culture, they were treated with different concentrations of compounds for 72 hours at 37°C under the condition of 5% CO 2 , and then MTS (final mass concentration 2mg/mL) Add the mixture of DMS and DMS (final molar concentration 30μM) directly into the medium containing the cells, and continue to incubate in the incubator for 4h. After acting for 4 hours, discard the supernatant, add 150 μ L DMSO to each well, shake, and the cell survival rate is measured by the absorption rate of the metabolites that act on MTS at the wavelength of 490 nm of the enzyme-linked immunosorbent monitor, FSHR antagonist drug molecule The inhibitory rate IC50 of this cell is 3.7μmol·L -1 , and the preliminary biological activity test shows that this compound has a certain inhibitory effect on prostate cancer cell DU145.
综上所述,本发明提供了一种具有6H-二苯并吡喃结构的FSHR拮抗剂及其制备方法,这是该类化合物该用途的首次发现,具有一定的研发潜力。In summary, the present invention provides a FSHR antagonist with a 6H-dibenzopyran structure and a preparation method thereof. This is the first discovery of this type of compound for this purpose, and has certain potential for research and development.
以上实施例描述了本发明的基本原理、主要特征及优点,本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。The above embodiments have described the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited by the above embodiments. What are described in the above embodiments and description are only to illustrate the principles of the present invention. Without departing from the scope of the principle of the present invention, there will be various changes and improvements in the present invention, and these changes and improvements all fall within the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710200791.6A CN106967076A (en) | 2017-03-30 | 2017-03-30 | One kind has 6H dibenzopyrans structural compounds and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710200791.6A CN106967076A (en) | 2017-03-30 | 2017-03-30 | One kind has 6H dibenzopyrans structural compounds and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106967076A true CN106967076A (en) | 2017-07-21 |
Family
ID=59335422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710200791.6A Withdrawn CN106967076A (en) | 2017-03-30 | 2017-03-30 | One kind has 6H dibenzopyrans structural compounds and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106967076A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101052641A (en) * | 2004-09-07 | 2007-10-10 | 惠氏公司 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
WO2013041461A1 (en) * | 2011-09-22 | 2013-03-28 | Msd Oss B.V. | Fsh receptor antagonists |
EP2459560B1 (en) * | 2009-07-29 | 2015-08-19 | Merck Sharp & Dohme B.V. | Ring-annulated dihydropyrrolo[2,l-a]isoquinolines |
WO2015196335A1 (en) * | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
CN105473596A (en) * | 2013-06-24 | 2016-04-06 | 默克专利有限公司 | Pyrazole compounds as modulators of FSHR and uses thereof |
-
2017
- 2017-03-30 CN CN201710200791.6A patent/CN106967076A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101052641A (en) * | 2004-09-07 | 2007-10-10 | 惠氏公司 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
EP2459560B1 (en) * | 2009-07-29 | 2015-08-19 | Merck Sharp & Dohme B.V. | Ring-annulated dihydropyrrolo[2,l-a]isoquinolines |
WO2013041461A1 (en) * | 2011-09-22 | 2013-03-28 | Msd Oss B.V. | Fsh receptor antagonists |
CN105473596A (en) * | 2013-06-24 | 2016-04-06 | 默克专利有限公司 | Pyrazole compounds as modulators of FSHR and uses thereof |
WO2015196335A1 (en) * | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019128983A1 (en) | Method for preparing elagolix intermediate and composition thereof | |
CN112851646B (en) | The preparation method of Tegrazan | |
WO2021023143A1 (en) | Method for preparing pharmaceutical intermediate of relugolix | |
WO2015154637A1 (en) | Method for preparing silodosin intermediate | |
CN113666883B (en) | Method for synthesizing 4-vinyl isoxazole derivative | |
CN108864127B (en) | A kind of oxygen-bridged bicycloheptene sulfonamide compounds containing different alkyl chain lengths and preparation method and application thereof | |
CN106674136A (en) | Anti-tumor pyrimidine compounds and preparation method thereof | |
CN101381389A (en) | Chemical Synthesis of 5,7-Diene Steroids | |
CN109705133B (en) | A Class of Selective Estrogen Receptor Modulator Compounds Containing Phenylselenide Group and Its Application in Anti-breast Cancer Drugs | |
CN106967076A (en) | One kind has 6H dibenzopyrans structural compounds and preparation method thereof | |
CN106588787B (en) | Application of an aroyl-containing 1,2,3-triazole ligand | |
CN104710367A (en) | Method for synthesizing enzalutamide | |
WO2020073984A1 (en) | Crystal form of opioid receptor (mor) agonist and preparation method thereof | |
CN110105222A (en) | A kind of novel processing step of 4- aminoidan class compound | |
CN107311946B (en) | Synthesis method of 2-(1H-1,2,3-triazolyl)-3-hydroxybiphenyl-4-carboxylic acid ethyl ester compounds | |
CN106977523A (en) | FSHR antagonists with phenyl and nafoxidine structure and preparation method thereof | |
WO2023197384A1 (en) | Cannabinol preparation method in copper-catalyzed one-pot process | |
CN103058832A (en) | Application of selective estrogen receptor modulator | |
CN106554254A (en) | A kind of synthetic method of 2,3 ', 4,5 ' tetrahydroxy bibenzyl of natural product | |
CN102336763B (en) | Synthesis method for pyranocoumarin derivatives | |
CN101696185A (en) | Synthesizing method of 6-nitro-S-(-)-indoline-2-carboxylic acid | |
CN114621218A (en) | Zolpidem intermediate compound | |
CN114890947B (en) | Aromatic heterocyclic compound containing quinoline structural unit, and preparation method and application thereof | |
CN106957320B (en) | The preparation method of biologically active benzo tetrahydropyrrole compounds | |
CN115819208B (en) | A kind of synthesis method of 2-aryl-3,4-dihydro-1(2H)-naphthone compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170721 |